Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
75,239 questions in 5,342 reviews
current versionsNo studies 15,213 · 20.2%Ungraded 10,323 · 13.7%Very low 17,528 · 23.3%Low 17,951 · 23.9%Moderate 11,190 · 14.9%High 3,034 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Prebiotics and anti‐inflammatory therapy vs anti‐inflammatory therapy Withdrawals due to adverse events · people with mild‐to‐moderate ulcerative colitis based on Truelove and Witts criteria Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | no estimate extracted | NR | No studies |
Prebiotics vs placebo Clinical relapse (6 months) · people with histologically confirmed diagnosis of ulcerative colitis in remission Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | RR 1.36 [0.79, 2.31] | 1 study · 89 participants | Low |
Prebiotics vs placebo Clinical improvement (partial Mayo score) (60 days) · people with histologically confirmed diagnosis of ulcerative colitis in remission Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | no estimate extracted | 1 study · 30 participants | Very low |
Prebiotics vs placebo Quality of life (IBDQ) (60 days) · people with histologically confirmed diagnosis of ulcerative colitis in remission Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | no estimate extracted | 1 study · 30 participants | Very low |
Prebiotics vs placebo Total adverse events (6 months) · people with histologically confirmed diagnosis of ulcerative colitis in remission Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | RR 1.68 [1.18, 2.4] | 1 study · 89 participants | Low |
Prebiotics vs placebo Clinical improvement (Rachmilewitz index) (14 days) · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10) Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | no estimate extracted | 1 study · 15 participants | Very low |
Prebiotics vs placebo Withdrawals due to adverse events (60 days to 6 months) · people with histologically confirmed diagnosis of ulcerative colitis in remission Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | RR 2.57 [1.15, 5.73] | 2 studies · 125 participants | Very low |
Prebiotics vs probiotics Clinical relapse (4 weeks) · people in remission or with mildly activeulcerative colitis Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | no estimate extracted | NR | No studies |
Prebiotics vs probiotics Clinical improvement · people in remission or with mildly activeulcerative colitis Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | no estimate extracted | NR | No studies |
Prebiotics vs probiotics Quality of life (IBDQ) (4 weeks) · people in remission or with mildly activeulcerative colitis Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | no estimate extracted | 1 study · 62 participants | Very low |
Prebiotics vs probiotics Total adverse events · people in remission or with mildly activeulcerative colitis Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | no estimate extracted | NR | No studies |
Prebiotics vs probiotics Withdrawals due to adverse events (4 weeks) · people in remission or with mildly activeulcerative colitis Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | RR 1 [0.44, 2.26] | 1 study · 80 participants | Very low |
Prebiotics vs synbiotics Clinical relapse (4 weeks) · people in remission or with mildly activeulcerative colitis Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | no estimate extracted | NR | No studies |
Prebiotics vs synbiotics Clinical improvement · people in remission or with mildly activeulcerative colitis Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | no estimate extracted | NR | No studies |
Prebiotics vs synbiotics Quality of life (IBDQ) (4 weeks) · people in remission or with mildly activeulcerative colitis Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | no estimate extracted | 1 study · 63 participants | Very low |
Prebiotics vs synbiotics Total adverse events · people in remission or with mildly activeulcerative colitis Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | no estimate extracted | NR | No studies |
Prebiotics vs placebo Quality of life (IBDQ) (2 or 3 months) · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10) Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | no estimate extracted | 1 study · 8 participants | Very low |
Prebiotics vs synbiotics Withdrawals due to adverse events (4 weeks) · people in remission or with mildly activeulcerative colitis Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | RR 1.13 [0.48, 2.62] | 1 study · 80 participants | Very low |
Prebiotics vs placebo Total adverse events · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10) Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | no estimate extracted | NR | No studies |
Prebiotics vs placebo Withdrawals due to adverse events (14 days to 2 or 3 months) · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10) Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | RR 2.73 [0.51, 14.55] | 2 studies · 31 participants | Very low |
Inulin and oligofructose 15 g vs inulin and oligofructose 7.5 g daily Clinical remission (9 weeks) · people with mild to moderately active ulcerative colitis Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | RR 4.27 [1.07, 16.96] | 1 study · 31 participants | Very low |
Inulin and oligofructose 15 g vs inulin and oligofructose 7.5 g daily Clinical improvement (Mayo score) (9 weeks) · people with mild to moderately active ulcerative colitis Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | RR 2.67 [1.06, 6.7] | 1 study · 31 participants | Very low |
Inulin and oligofructose 15 g vs inulin and oligofructose 7.5 g daily Quality of life · people with mild to moderately active ulcerative colitis Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | no estimate extracted | NR | No studies |
Inulin and oligofructose 15 g vs inulin and oligofructose 7.5 g daily Total adverse events (9 weeks) · people with mild to moderately active ulcerative colitis Prebiotics for induction and maintenance of remission in ulcerative colitis (2024) · Cochrane | RR 1.71 [0.72, 4.06] | 1 study · 31 participants | Very low |
Test‐based attendance vs routine isolation after contact with a SARS‐CoV‐2‐positive person Rates of symptomatic PCR‐positive SARS‐CoV‐2 infection (over 13‐week · school staff Workplace interventions to reduce the risk of SARS‐CoV‐2 infection outside of healthcare settings (2024) · Cochrane | RR 1.28 [0.74, 2.21] | 1 study · 24027 participants | Very low |
Test‐based attendance vs routine isolation after contact with a SARS‐CoV‐2‐positive person Rates of any PCR‐positive SARS‐CoV‐2 infection (over 13‐week · school staff Workplace interventions to reduce the risk of SARS‐CoV‐2 infection outside of healthcare settings (2024) · Cochrane | RR 1.35 [0.82, 2.21] | 1 study · 24027 participants | Very low |
Test‐based attendance vs routine isolation after contact with a SARS‐CoV‐2‐positive person SARS‐CoV‐2‐related mortality · school staff Workplace interventions to reduce the risk of SARS‐CoV‐2 infection outside of healthcare settings (2024) · Cochrane | no estimate extracted | NR | No studies |
Test‐based attendance vs routine isolation after contact with a SARS‐CoV‐2‐positive person Adverse events · school staff Workplace interventions to reduce the risk of SARS‐CoV‐2 infection outside of healthcare settings (2024) · Cochrane | no estimate extracted | NR | No studies |
Test‐based attendance vs routine isolation after contact with a SARS‐CoV‐2‐positive person COVID‐related absenteeism from work Days absent per 1000 working days (over 13‐week · school staff Workplace interventions to reduce the risk of SARS‐CoV‐2 infection outside of healthcare settings (2024) · Cochrane | RR 0.83 [0.55, 1.25] | 1 study · 24027 participants | Low |
Test‐based attendance vs routine isolation after contact with a SARS‐CoV‐2‐positive person All‐cause mortality · school staff Workplace interventions to reduce the risk of SARS‐CoV‐2 infection outside of healthcare settings (2024) · Cochrane | no estimate extracted | NR | No studies |
Test‐based attendance vs routine isolation after contact with a SARS‐CoV‐2‐positive person Quality of life · school staff Workplace interventions to reduce the risk of SARS‐CoV‐2 infection outside of healthcare settings (2024) · Cochrane | no estimate extracted | NR | No studies |
Test‐based attendance vs routine isolation after contact with a SARS‐CoV‐2‐positive person Hospitalisation · school staff Workplace interventions to reduce the risk of SARS‐CoV‐2 infection outside of healthcare settings (2024) · Cochrane | no estimate extracted | NR | No studies |
Test‐based attendance vs routine isolation after contact with a SARS‐CoV‐2‐positive person Adherence to strategies: uptake of rapid antigen test (over 13‐week · school staff Workplace interventions to reduce the risk of SARS‐CoV‐2 infection outside of healthcare settings (2024) · Cochrane | no estimate extracted | 1 study · 253 participants | Ungraded |
Respiratory syncytial virus vaccine vs placebo Infant hospitalisation with laboratory‐confirmed RSV disease · pregnant woman Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes (2024) · Cochrane | RR 0.5 [0.31, 0.82] | 4 studies · 12216 participants | High |
Respiratory syncytial virus vaccine vs placebo Infant hospitalisation with clinically confirmed RSV disease · pregnant woman Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes (2024) · Cochrane | no estimate extracted | NR | No studies |
Respiratory syncytial virus vaccine vs placebo Intrauterine growth restriction · pregnant woman Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes (2024) · Cochrane | RR 1.32 [0.75, 2.33] | 4 studies · 12545 participants | Moderate |
Respiratory syncytial virus vaccine vs placebo Stillbirth · pregnant woman Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes (2024) · Cochrane | RR 0.81 [0.38, 1.72] | 5 studies · 12652 participants | Low |
Respiratory syncytial virus vaccine vs placebo Maternal death · pregnant woman Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes (2024) · Cochrane | RR 3 [0.12, 73.5] | 3 studies · 7977 participants | Low |
Respiratory syncytial virus vaccine vs placebo Preterm birth · pregnant woman Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes (2024) · Cochrane | RR 1.16 [0.99, 1.36] | 6 studies · 17560 participants | Very low |
Respiratory syncytial virus vaccine vs placebo Congenital abnormalities · pregnant woman Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes (2024) · Cochrane | RR 0.96 [0.88, 1.04] | 4 studies · 12304 participants | High |
Respiratory syncytial virus vaccine vs placebo Infant death · pregnant woman Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes (2024) · Cochrane | RR 0.81 [0.36, 1.81] | 6 studies · 17589 participants | Very low |
Full‐face filtering masks vs no respiratory protection Reduction in exposure to asbestos · asbestos workers Personal protective equipment for preventing asbestos exposure in workers (2024) · Cochrane | no estimate extracted | NR | No studies |
Powered air‐purifying respirators vs no respiratory protection Asbestos concentration reduction · asbestos workers Personal protective equipment for preventing asbestos exposure in workers (2024) · Cochrane | no estimate extracted | NR | Moderate |
Powered air‐purifying respirators vs no respiratory protection Asbestos exposure after doffing · asbestos workers Personal protective equipment for preventing asbestos exposure in workers (2024) · Cochrane | no estimate extracted | NR | No studies |
Powered air‐purifying respirators vs no respiratory protection Donning and doffing errors · asbestos workers Personal protective equipment for preventing asbestos exposure in workers (2024) · Cochrane | no estimate extracted | NR | No studies |
Powered air‐purifying respirators vs no respiratory protection Adverse effects · asbestos workers Personal protective equipment for preventing asbestos exposure in workers (2024) · Cochrane | no estimate extracted | NR | No studies |
One type of coverall vs another type of coverall Asbestos concentration · asbestos workers Personal protective equipment for preventing asbestos exposure in workers (2024) · Cochrane | no estimate extracted | NR | No studies |
One type of coverall vs another type of coverall Asbestos concentration after doffing · asbestos workers Personal protective equipment for preventing asbestos exposure in workers (2024) · Cochrane | no estimate extracted | NR | No studies |
One type of coverall vs another type of coverall Donning and doffing errors · asbestos workers Personal protective equipment for preventing asbestos exposure in workers (2024) · Cochrane | no estimate extracted | NR | No studies |
One type of coverall vs another type of coverall Adverse effects: core body temperature (change from before to after work) · asbestos workers Personal protective equipment for preventing asbestos exposure in workers (2024) · Cochrane | no estimate extracted | 1 study · 11 participants | Low |